Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dialysis01:27

Dialysis

277
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
277
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

2.3K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.3K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

62
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
62
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

133
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
133
Drug Elimination by Renal Route: Glomerular Filtration01:17

Drug Elimination by Renal Route: Glomerular Filtration

5.5K
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production takes place. A nephron has two main components: a renal corpuscle and a renal tubule. Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent...
5.5K
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

153
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
153

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression and Characterization of a Recombinant Laccase with Alkalistable and Thermostable Properties from Streptomyces griseorubens JSD-1.

Applied biochemistry and biotechnology·2015
Same author

Herb-Partitioned Moxibustion and the miRNAs Related to Crohn's Disease: A Study Based on Rat Models.

Evidence-based complementary and alternative medicine : eCAM·2015
Same author

Bioactive carbazole alkaloids from the stems of Clausena lansium.

Fitoterapia·2015
Same author

Clauemarazoles A-G, seven carbazole alkaloids from the stems of Clausena emarginata.

Fitoterapia·2015
Same author

Scalable and DiI-compatible optical clearance of the mammalian brain.

Frontiers in neuroanatomy·2015
Same author

FSH regulates fat accumulation and redistribution in aging through the Gαi/Ca(2+)/CREB pathway.

Aging cell·2015

Related Experiment Video

Updated: Jun 14, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

525

Current progress in CAR-based therapy for kidney disease.

Dan Zhang1, Dong Sun1,2,3

  • 1Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Frontiers in Immunology
|September 5, 2024
PubMed
Summary
This summary is machine-generated.

Chimeric antigen receptor (CAR) T-cell therapy shows promise for treating immune-mediated kidney diseases. This approach engineers T cells to target and suppress autoimmune cells, offering new hope for refractory cases.

Keywords:
T lymphocytesautoimmune diseasescell immunotherapychimeric antigen receptor T cell therapykidney disease

More Related Videos

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.2K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.5K

Related Experiment Videos

Last Updated: Jun 14, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

525
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.2K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.5K

Area of Science:

  • Immunology
  • Nephrology
  • Cell Therapy

Background:

  • Immune-mediated kidney diseases present challenges due to poor treatment responses in some patients.
  • Existing therapies are insufficient for refractory renal disease cases.
  • Engineered T cells offer a novel therapeutic avenue for kidney diseases.

Purpose of the Study:

  • To review advancements in chimeric antigen receptor (CAR) T-cell therapies for immune-mediated kidney diseases.
  • To highlight the potential of CAR T-cell therapy in basic, translational, and clinical research.
  • To explore CAR T-cell applications in targeting autoreactive immune cells and alleviating autoimmune kidney conditions.

Main Methods:

  • Genetic modification of T cells to express chimeric antigen receptors (CARs).
  • Targeting autoreactive immune cells, including B cells and plasma cells.
  • Utilizing effector and regulatory T cells (Tregs) for autoimmune site-specific therapy.

Main Results:

  • CAR T-cell therapy enables precise targeting of autoimmune cells implicated in kidney disease.
  • Engineered T cells can migrate to sites of autoimmunity, proliferate, and exert suppressive functions.
  • This approach offers a novel strategy for alleviating autoimmune manifestations in the kidneys.

Conclusions:

  • CAR T-cell therapy represents a promising frontier for treating immune-mediated kidney diseases.
  • Genetically modified T cells provide a new mechanism to reduce autoinflammatory events.
  • Further research and clinical studies are warranted to fully realize the therapeutic potential of CAR T-cell interventions.